Related Experiment Video
Updated: Jul 12, 2026

Quantification of Immunostained Caspase-9 in Retinal Tissue
Published on: July 25, 2022
Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression.
Jeong Hun Kim1, Ki Hyun Kim, Jin Hyoung Kim
1Department of Ophthalmology, College of Medicine, Seoul National University, and Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, Seoul 110-744, Republic of Korea.
Homoisoflavanone, a natural compound, effectively reduces eye neovascularization in a retinopathy of prematurity mouse model. This finding suggests potential therapeutic applications for vision loss conditions like retinopathy of prematurity.
Area of Science:
- Ophthalmology
- Pharmacology
- Cell Biology
Background:
- Ocular neovascularization causes blindness, with retinopathy of prematurity (ROP) being a major concern in children.
- Current treatments for ROP have limitations, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of homoisoflavanone, a natural product, in inhibiting retinal neovascularization.
- To explore the cellular mechanisms underlying homoisoflavanone's effects on vascular endothelial cells.
Main Methods:
- A mouse model of retinopathy of prematurity was used to assess homoisoflavanone's effect on retinal neovascularization.
- Human Umbilical Vein Endothelial Cells (HUVECs) were treated with homoisoflavanone to evaluate its impact on cell growth and cell cycle progression.
- Western blot analysis was performed to examine the expression levels of cell cycle regulatory proteins (cdc2 and p21WAF1).
Main Results:
- Homoisoflavanone significantly reduced retinal neovascularization in the ROP mouse model.
- The compound inhibited HUVEC cell growth without significant cytotoxicity at concentrations of 1-20 microM.
- Homoisoflavanone induced cell cycle arrest at the G2/M phase and altered the expression of cdc2 and p21WAF1 in a dose-dependent manner.
Conclusions:
- Homoisoflavanone demonstrates potent anti-neovascularization properties in the context of retinopathy of prematurity.
- The findings suggest that homoisoflavanone may serve as a potential therapeutic agent for treating various vasoproliferative retinopathies.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Diabetic Retinopathy
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibitors of Virion Maturation and Assembly
Negative Regulator Molecules

